Table 1 Laboratory and clinical characteristics of r-GPA patients and HC

Subjects, n (% male)

63 (% 44)

42 (% 40)

Age, mean (range)

62.3 (26.8–85.2)

57.2 (21.5–86.8)

PR3-ANCA^a, n (% positive)

39 (% 62)

PR3-ANCA titer, median (range)

1:40 (0–1:640)

Creatinine umol/L, median (range)

86 (52–224)

CRP mg/L, median (range)

2.7 (0.3–99)

eGFR ml/min*1.73 m², median (range)

64 (21–109)

CMV seropositive, n (% positive) (N.D.)

33 (% 54) (2)

21 (% 58) (6)

S. aureus, n (% positive) (N.D.)

27 (% 44) (1)

BVAS, mean

0

Disease duration in years, median (range)

9.6 (1.9–42.7)

No. of total relapses, median (range)

1 (0–7)

Relapser^b, n (%)

43 (% 68)

Disease type, n (% generalized)

52 (% 83)

 Azathioprine

3 (% 5)

 Azathioprine + prednisolone

12 (% 19)

 Prednisolone

6 (% 10)

 Mycophenolate mofetil + prednisolone

7 (% 11)

 Methotrexate

1 (% 2)

 No immunosupressive treatment

34 (% 54)

Co-trimoxazole, high dose/low dose/no dose

17/15/31

No. of organs involved, median (range)

3 (1–7)

 Renal

35 (% 56)

 ENT

45 (% 71)

 Joints

36 (% 57)

 Pulmonary

40 (% 63)

 Nervous system

20 (% 32)

 Eyes

24 (% 38)

 Cutaneous

13 (% 21)

 Other

7 (% 11)